Wei Wang, PhD, DABT

Director
Eli Lilly and Company, Inc.
Indianapolis, Indiana, United States

Presentation(s):

• Nonclinical Program Considerations for Peptide Safety Assessment (S02)

  Monday, November 18, 2024
  9:00 AM - 12:00 PM CT

• EFPIA Peptide Safety Working Group Survey Results (S02-3)

  Monday, November 18, 2024
  9:50 AM - 10:15 AM CT